H.C. Wainwright lowered the firm’s price target on Transcode Therapeutics (RNAZ) to $10 from $20 and keeps a Buy rating on the shares. The firm ...

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam ...

Fintel reports that on April 11, 2025, HC Wainwright & Co. initiated coverage of Richtech Robotics (NasdaqCM:RR) with a Buy ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to the asset.,The event adheres to common market appraisal procedures.,Within ...

HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.15).

Richtech Robotics (NASDAQ:RR) rallied in late Friday morning trading after H.C. Wainwright initiated coverage on the stock with a Buy rating. Analyst Scott Buck pointed to favorable secular ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price ...

Fintel reports that on April 11, 2025, HC Wainwright & Co. initiated coverage of Richtech Robotics (NasdaqCM:RR) with a Buy recommendation. There are 35 funds or institutions reporting positions ...